S-1/A: Picard Medical IPO Faces Going Concern Doubts Amid Losses

Picard Medical, Inc. is pursuing an initial public offering of 4.25 million shares at $3.50-$4.50 per share to fund operations and product development, despite a history of significant net losses and substantial doubt about its ability to continue as a going concern.

Summary

• Picard Medical, Inc. (PMI) is offering 4,250,000 shares of common stock in its initial public offering (IPO) at an estimated price range of $3.50 to $4.50 per share, aiming to raise approximately $15.4 million in net proceeds.
• The company, through its subsidiary SynCardia Systems, LLC, manufactures and sells the SynCardia Total Artificial Heart (TAH), the only FDA and Health Canada approved implantable total artificial heart for bridge to heart transplantation (BTT).
• Over 2,100 SynCardia TAHs have been implanted in patients across 27 countries.
• PMI has incurred significant net losses, including $21.1 million in 2024 and $5.6 million for the three months ended March 31, 2025, leading to an accumulated deficit of $55.4 million as of March 31, 2025.
• The company's independent registered public accounting firm has raised substantial doubt about its ability to continue as a going concern.
• Revenue decreased by 13% to $4.391 million in 2024 from $5.043 million in 2023, and by 69% to $0.620 million for Q1 2025 compared to $1.980 million for Q1 2024.
• PMI is developing new products, including the fully implantable Emperor Total Artificial Heart (expected FDA approval 2028), and upgraded portable (Freedom+) and hospital (Companion 3) drivers (expected FDA approvals late 2025, late 2026, and late 2027 respectively).
• The company is seeking to expand the SynCardia TAH's indications for use to include Bridge to Candidacy (BTC) and long-term use (24 months or more), with FDA feedback expected in Q2 2026 for BTC and removal of 'imminent death' from IFU.
• PMI voluntarily cancelled its EU CE mark in July 2022 due to post-market surveillance deficiencies and is planning to reapply for an MDR CE mark in Q4 2025.
• A field correction was initiated for cannula tears in the SynCardia TAH, with 104 reports but zero Serious Adverse Events as of March 20, 2025; a design change submission to FDA is expected in Q3 2025.
• Hunniwell Picard I, LLC will control 54.8% of outstanding common stock post-IPO, making PMI a controlled company and allowing reliance on certain NYSE American corporate governance exemptions.
• The company relies on single-source suppliers for critical components of its drivers and valves, posing a supply chain risk.
• Proceeds from the IPO are intended for market expansion in China ($2.85 million), R&D activities ($3.36 million), sales and marketing ($0.50 million), working capital ($0.5 million), general operational expenses ($0.39 million), and repayment of related party debt ($5.6 million Senior Secured Notes and $2.0 million working capital loans).

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant and increasing net losses, a substantial accumulated deficit, and a formal 'going concern' warning from auditors. While the company has a unique FDA-approved product and a promising pipeline, its current financial health, declining revenues, and heavy reliance on the IPO to fund operations and repay debt present considerable risks. The loss of the EU CE mark and single-source supplier dependencies further contribute to the negative outlook, despite some positive developments in product innovation and market expansion efforts.

Positives

• SynCardia TAH is the only U.S. FDA and Health Canada approved implantable total artificial heart, providing a unique market position.
• Over 2,100 SynCardia TAHs have been implanted globally across 27 countries, demonstrating extensive clinical experience and an established presence.
• The company has a robust product pipeline, including the fully implantable Emperor TAH and next-generation portable and hospital drivers (Freedom+, Companion 3, Unicorn), aiming to expand indications for use to Bridge to Candidacy and long-term support.
• Existing technology (heart ventricles with SPUS material) has over 2,100 implants worth of clinical experience, providing a strong foundation for future innovations.
• The SynCardia TAH procedure is eligible for DRG 001, the highest possible reimbursement under Medicare, with private insurers also reporting success in securing reimbursement.
• PMI holds six awarded U.S. and international patents and has over twelve pending, including new patents for its next-generation total artificial heart technology.
• The company maintains an ISO 13485-certified quality management system and has successfully completed MDSAP audits with no deficiencies, indicating strong manufacturing and quality control.
• Competitors like Carmat SA are facing significant challenges, including insolvency proceedings and software issues, which may reduce competitive pressure.
• PMI has a successful training and education program for surgeons and clinical teams, informed by over 30 years of experience and 2,100+ implants.
• The company is actively pursuing international market expansion, including a joint venture in China and discussions with potential distributors in Taiwan, the Gulf region, India, and Brazil.

Negatives

• The company has a history of significant net losses, including $21.1 million in 2024 and $5.6 million in Q1 2025, and expects to continue incurring losses for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern, as stated by its independent registered public accounting firm.
• Total revenue decreased by 13% in 2024 compared to 2023, and by a significant 69% in Q1 2025 compared to Q1 2024, indicating a declining sales trend.
• The company voluntarily cancelled its EU CE mark in July 2022 due to post-market surveillance deficiencies and is working to reapply under new, more stringent MDR regulations, with no guarantee of timely approval.
• PMI relies on single-source suppliers for critical components of its drivers and valves, creating significant supply chain risk if these suppliers cease operations or terminate commercial ties.
• Many aspects of the SynCardia TAH are no longer protected by patents, increasing vulnerability to competition.
• The company has significant customer concentrations, with a small number of customers accounting for a substantial portion of revenues, making it vulnerable to changes in their purchasing policies or economic difficulties.
• The company has a substantial accumulated deficit of $55.4 million as of March 31, 2025.
• The company has significant debt, including $23.505 million as of December 31, 2024, and $31.918 million as of March 31, 2025, with a large portion being current convertible notes and related party loans.
• The company's total cost of revenue as a percentage of total sales was 158% for Q1 2025, indicating negative gross margins.
• The company's current products and future products may not gain widespread market acceptance, particularly given existing alternatives like LVADs and the invasive nature of TAH implantation.
• The company has experienced production delays associated with selecting and engaging alternative suppliers for certain components.
• The company has a significant working capital deficit of $30.435 million as of March 31, 2025.
• The company does not intend to pay cash dividends for the foreseeable future, limiting investor returns.
• The company will incur increased costs and demands upon management as a result of complying with laws and regulations affecting public companies.

Risks

• History of significant losses and inability to achieve and sustain profitability, leading to substantial doubt about continuing as a going concern.
• Reliance on a limited number of products (SynCardia TAH) for substantially all revenue, making the business vulnerable to any decline in sales or failure to gain market acceptance.
• Manufacturing of SynCardia TAH requires highly specialized knowledge and operator skills, and the loss of key personnel could result in production delays.
• Reliance on specialized single-source suppliers for crucial components (e.g., Bimba/Heitek Automation for driver components, SynHall Valves) without readily available second sources, posing supply chain risks.
• Significant customer concentrations, with a small number of customers accounting for a substantial portion of revenues, leading to potential revenue fluctuations if these relationships change.
• Future success depends on timely development, regulatory approval, and market acceptance of new products or enhancements, which is a lengthy, expensive, and unpredictable process.
• Inability to successfully complete pre-clinical studies or clinical trials necessary for regulatory approvals (e.g., for long-term indication of SynCardia TAH or new products like Emperor).
• Third-party payors may not continue to provide adequate coverage and reimbursement for products, negatively impacting demand and revenues.
• Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact business and operating results.
• Credit risk from accounts receivable, especially from foreign customers in economically unstable regions.
• Exposure to currency fluctuations due to international operations, which could impact results.
• Changes in U.S. and foreign tax laws could materially affect financial position and results.
• Industry and market-related estimates may prove inaccurate, leading to overestimation of market opportunity.
• Inability to attract and retain highly qualified personnel due to intense competition in the medical device industry.
• Risks associated with future acquisitions, including integration difficulties, loss of key employees, and financial impact.
• Failure to protect information technology infrastructure against cyber-based attacks, network security breaches, service interruptions, or data corruption.
• Failure to protect the product and patient from cybersecurity risks associated with using the device, especially with future designs incorporating more connectivity.
• Demand for total artificial hearts depends on various factors, and medical advances could provide better alternatives, decreasing demand for SynCardia TAHs.
• Extensive governmental regulation (FDA, CE mark, Health Canada, NMPA) makes product introduction expensive and time-consuming, with potential for delays, denials, or post-market restrictions.
• Off-label use or misuse of products could harm reputation, lead to product liability suits, or regulatory sanctions.
• Requirement to comply with medical device reporting (MDR) requirements, with potential for recalls, costs, and enforcement actions.
• Risk of employee misconduct or improper activities, including non-compliance with regulatory standards and healthcare fraud and abuse laws.
• Prior weaknesses in CE MDD regulatory compliance may limit ability to market or sell products in European markets.
• Many aspects of the SynCardia TAH are no longer protected by patents, increasing vulnerability to competition and potential intellectual property litigation.
• Risk of claims related to inadvertent or intentional use or disclosure of trade secrets or proprietary information of former employers by employees.
• Share price volatility and potential for substantial losses for purchasers of securities.
• Classification as an emerging growth company and smaller reporting company may make securities less attractive to investors due to reduced disclosure requirements.
• Future sales of common stock or the perception of such sales may cause the market price to decline due to potential dilution.
• Increased costs and demands on management due to compliance with public company laws and regulations.
• Potential for securities class action or derivative litigation, leading to substantial costs and diversion of management attention.
• Inability to implement and maintain effective internal control over financial reporting, leading to loss of investor confidence.
• No prior public market for common stock, and an active trading market may not develop or be sustained.
• Significant dilution to stockholders upon conversion of certain convertible notes and preferred shares.
• Reliance on controlled company corporate governance exemptions, which may afford stockholders fewer protections.
• Exclusive forum provisions in the Charter could limit stockholders' ability to bring claims in preferred judicial forums.

Future Outlook

Picard Medical's future vision is to develop the world's first fully implantable SynCardia TAH as an alternative to heart transplantation, with FDA approval for the Emperor system potentially by 2028. Near-term plans include innovating current driver technology to expand the SynCardia TAH's indication for use from Bridge to Transplantation (BTT) to Bridge to Candidacy (BTC) and for long-term use of two years or more, with FDA feedback on these expansions expected in Q2 2026. The company also anticipates FDA approval for an upgraded portable driver (Freedom+) by the second half of 2025, and next-generation Freedom and C2 Drivers by the second halves of 2026 and 2027, respectively. International market expansion, particularly in China, India, and the Middle East, is a key strategic driver for future success.

Management Comments

• Management believes that based on their technology, intellectual property, know-how, and extensive human clinical experience, they have significant advantages over other companies developing other TAH products.
• Management expects to continue to incur significant expenses and operating losses for the foreseeable future due to heavy investment in product development and the costs of operating as a public company.
• Management believes that their existing cash and cash equivalents as of December 31, 2024, and anticipated expenditures for the next twelve months, will not enable them to fund operating expenses and capital expenditure requirements for the twelve months from December 31, 2024, leading to substantial doubt about their ability to continue as a going concern.
• Management expects to raise sufficient cash to fund operations into 2025 based on current business plans and macroeconomic conditions, but acknowledges these plans are not finalized and there's no assurance of successful capital raising.
• Management states that the company can scale up SynCardia TAH production in Tucson, AZ to approximately 450 units per year depending on expected demand.
• Management considers their relationship with employees to be good.
• Management believes that their trade secrets protecting SPUS (Segmented Polyurethane Solution) and its biocompatibility are likely to present a major barrier to potential competitors.
• Management believes that the SynCardia TAH is a complementary treatment alternative to LVADs on the continuum of care, despite physicians being accustomed to LVADs.

Industry Context

The medical device industry, particularly for cardiovascular treatments, is highly competitive and subject to rapid technological change. Heart failure is a leading cause of death globally, with millions affected and a significant demand for heart transplants that far exceeds supply. This creates a critical need for mechanical circulatory support devices like total artificial hearts. Picard Medical's SynCardia TAH holds a unique position as the only FDA and Health Canada approved device in its category, giving it a competitive edge over emerging competitors like Carmat (which recently filed for insolvency) and BiVACOR (still in early clinical testing). However, the market also includes established players offering Left Ventricular Assist Devices (LVADs) and temporary MCS, which are less invasive but do not replace both ventricles. The industry faces challenges related to lengthy and unpredictable regulatory approval processes, reimbursement policies, and the need for continuous innovation to improve patient outcomes and quality of life.

Comparison to Industry Standards

• The SynCardia TAH is the only total artificial heart approved for commercial use in the United States and Canada, providing a significant regulatory advantage over competitors.
• Compared to Carmat's Aeson device, SynCardia TAH has significantly more implants (over 2,100 vs. 108 as of July 2025) and a lighter implant weight (250g vs. 900g), allowing it to serve a broader patient population including women and children.
• Carmat's Aeson device, while CE marked in Europe, recently filed for insolvency and experienced software issues, highlighting potential instability and quality concerns not present with SynCardia's current product.
• BiVACOR's system is in early-stage human clinical testing (5 of 20 patients enrolled in EFS) and has no market approvals to date, positioning SynCardia as a much more clinically advanced and commercially available option.
• The SynCardia TAH replaces both left and right ventricles and all four heart valves, offering full biventricular support, unlike LVADs (e.g., Abbott HeartMate 3) which only support the left ventricle.
• SynCardia TAH patients can be discharged home with the portable Freedom Driver, unlike temporary MCS devices (e.g., ECMO, axial flow LVADs) which are typically for hospital use only and limited to short-term support (less than two weeks).
• The SynCardia TAH's cardiac output (up to 10.5 liters/minute for 70cc, 7.5 liters/minute for 50cc) significantly exceeds a normal human heart's average (5.6 liters/minute) and the minimum viable cardiac output (~2.5-3.0 liters/minute), indicating strong circulatory support.
• Clinical efficacy studies for SynCardia TAH show 1-year survival rates ranging from 75% to 86.6% in real-world data settings, confirming and expanding upon the 2004 FDA PMA study findings (79% survival to transplantation, 70% 1-year survival post-implant).
• Neurological event rates in real-world data for SynCardia TAH patients (5% of total adverse events) compare favorably to the PMA FDA study (27% for all implanted patients, 5% for per-protocol patients), suggesting improved outcomes or reporting consistency.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the prospectus, the company is not a party to any material legal matters or claims.
• The company may become party to legal matters and claims in the ordinary course of business in the future, but does not anticipate them having a material adverse impact on financial position, results of operations, or cash flows.

Related Party Transactions

• In 2024, the company sent 136 lots of TAH product to SynCardia Medical (Beijing), Inc. for regulatory registration inspection and testing.
• As of July 9, 2025, various related party or affiliated loans in the form of working capital loans and convertible notes are outstanding.
• A $100,000 unsecured promissory note from Versa Capital Management, LLC (affiliated with Sindex SSI Financing, LLC) from September 27, 2021, remains uncollected, with a balance of $112,000 including accrued interest as of March 31, 2025.
• Between June 2023 and June 2024, the company borrowed a total of $9,320,000 from Hunniwell and Fang Family Funds (affiliated with executive directors), with $880,000 repaid to Hunniwell and $1,150,000 repaid to Fang Family Funds.
• A $300,000 loan from a limited partner in Hunniwell, bearing 6% interest, is outstanding as of September 25, 2023, and will automatically convert into common stock upon IPO.
• Effective July 2, 2024, approximately $7.0 million in loans from Richard Fang and Fang Family Funds were consolidated into one convertible note (FFF Convertible Note), accruing 6% simple interest, and will automatically convert into common stock at a 50% discount to the IPO price upon IPO.
• On November 12, 2024, Richard Fang donated the $7.0 million FFF Convertible Note and accrued interest to unrelated non-profit organizations, Nexus Science Foundation Inc. and Another Dimension Foundation, which will each receive 50% of the converted value in registered shares.
• Between June 25 and December 31, 2024, the company borrowed $5,070,000 from Fang Family Fund II, LLC and $250,000 from Hunniwell; $1,660,000 of these are interest-free, $580,000 bears SOFR interest, and $2,830,000 are secured by company assets at 6% interest.
• On July 1, 2025, a $250,000 related party working capital loan (from August 20, 2024) was amended, and new loans of $93,633 to Hunniwell (travel expense reimbursements) and $187,190 to Daniel Teo (severance) were issued under the same Senior Secured Notes terms, with maturity extended to October 15, 2025.
• Between January 9 and March 21, 2025, the company borrowed a further $1,352,000 from Fang Family Funds, secured by company assets at 6% interest, with maturity extended to October 15, 2025.
• On April 30, 2025, the company borrowed $90,000 from Fang Family Fund I LLC, secured by company assets at 6% interest, with maturity extended to October 15, 2025.
• On June 24, 2025, the company borrowed $310,000 from Fang Family Fund I, LLC, secured by company assets at 6% interest, with maturity extended to October 15, 2025.
• On July 8, 2025, the company borrowed $425,000 from Fang Family Fund I, LLC, secured by company assets at 6% interest, due October 15, 2025.
• On July 7, 2025, Hunniwell exercised its option to convert all of its preferred stock to 39,618,919 shares of common stock.

Stakeholder Impact

• **Shareholders:** Will experience significant dilution from the IPO and conversion of preferred shares and convertible notes. Existing shareholders will see their ownership interest immediately diluted by $3.94 per share. Future sales of common stock could cause further price decline. The company does not intend to pay cash dividends in the foreseeable future.
• **Employees:** The company considers its relationship with employees to be good. Stock-based compensation is a component of executive compensation. The company is actively increasing its sales specialists and clinical support staff. However, the 'going concern' doubt could create uncertainty regarding job security and future growth opportunities.
• **Customers (Hospitals/Surgeons):** Continued availability of SynCardia TAH and its components is critical. Risks related to single-source suppliers and potential production delays could impact product availability. The voluntary cancellation of the EU CE mark affects European market access. Reimbursement policies are crucial for hospitals' willingness to use the product.
• **Suppliers:** The company relies on specialized single-source suppliers for critical components, making them key stakeholders. Any disruption in these relationships (e.g., Bimba, Heitek Automation) could severely impact the company's ability to manufacture products.
• **Creditors:** The company has significant outstanding debt, including related party loans and convertible notes, some of which are past due. The 'going concern' warning indicates a high risk for creditors, although the IPO proceeds are partly allocated to debt repayment. The security interests granted on company assets to certain lenders provide some protection.

Next Steps

• Complete the initial public offering (IPO) to raise approximately $15.4 million in net proceeds.
• Fund SynCardia Medical (Beijing), Inc. with $2.85 million to support market expansion in China.
• Continue research and development activities for the fully implantable Emperor system, with acute animal studies planned for the second half of 2025 and potential FDA approval by 2028.
• Continue development of upgraded portable (Freedom+) and hospital (Companion 3) drivers, with anticipated FDA approvals in late 2025, late 2026, and late 2027 respectively.
• Pursue FDA approval for expanded indications of the SynCardia TAH to include Bridge to Candidacy (BTC) and long-term use (24 months or more), with FDA feedback on the PMA supplement expected in Q2 2026.
• Complete validation activities for the design change to address cannula tears and submit a 180-Day PMA Supplement to the FDA in approximately Q3 2025.
• Reapply for an MDR CE mark in the European Union during Q4 2025.
• Develop the Unicorn driver system working prototype into a testable commercial product and complete regulatory testing by the second half of 2026, with FDA approval expected mid-2027.
• Build sales, marketing, and distribution capabilities for the total artificial heart system, including additional inventory and drivers.
• Repay $5.6 million in Senior Secured Notes and approximately $2.0 million in working capital related party loans.
• Work with lenders to extend the maturity dates of past-due convertible notes (Nexus and Another Dimension notes, and $3.7 million of 2024 Convertible Notes).
• Continue to attract and retain highly qualified personnel, especially sales, scientific, and management staff.
• Implement and maintain effective internal control over financial reporting as a public company.
• Appoint additional independent directors to meet NYSE American listing rules for audit, compensation, and nominating/corporate governance committees within the phase-in period.

Key Dates

Recommendation

Picard Medical presents a high-risk investment opportunity. The company has a history of significant and increasing net losses, a substantial accumulated deficit, and its independent auditors have raised 'substantial doubt' about its ability to continue as a going concern. Revenue has seen a sharp decline, particularly in Q1 2025. While the company possesses a unique FDA-approved product and a promising pipeline, its financial instability, heavy reliance on the IPO proceeds for survival and debt repayment, and significant operational risks (single-source suppliers, regulatory hurdles in Europe) outweigh the potential upside. The planned IPO is primarily a capital raise to address immediate liquidity issues and debt, rather than to fuel profitable growth from a strong financial base. Seasoned investors would likely view this as a distressed situation with a high probability of further dilution or financial restructuring if the IPO is not fully successful or if operational improvements do not materialize rapidly. The concentration of ownership post-IPO also limits minority shareholder influence. Therefore, a 'sell' recommendation is appropriate, especially for existing shareholders, and new investors should exercise extreme caution or avoid.

Keywords

Total Artificial Heart, SynCardia TAH, Medical Device, Heart Failure, IPO, FDA Approval, CE Mark, Bridge to Transplant, Biventricular Failure, Emperor TAH, Freedom Driver, Pneumatic Driver, Cardiovascular Disease, Biomedical Engineering, Medical Technology, SEC Filing, S-1/A, Going Concern, Clinical Trials, Intellectual Property, Regulatory Compliance, Capital Raise, NYSE American